膣炎治療薬の世界市場レポート 2025年

膣炎治療薬市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.8％で67億2,000万米ドルに成長します。予測期間の成長は、個別化医療への重点の高まり、ヘルスケアへのアクセスの増加、高齢化人口の増加、非抗生物質療法への注力、啓発・教育イニシアティブなどに起因すると考えられます。予測期間の世界の動向には、耐性症例に対する併用療法、規制の進歩とガイドライン、デジタルヘルスツールの統合、研究のための世界的協力、非薬物療法の開発などが含まれます。

性感染症（STD）の有病率の上昇は、今後の膣炎治療薬市場の成長を牽引すると予想されます。STDは、感染者と非感染者の性的接触によって感染する感染症で、膣炎を引き起こし、膣の炎症や痛みにつながります。膣炎治療薬は、STDによる膣炎に伴う症状を緩和する目的で開発された医薬品であるため、女性の使用率が高くなっています。例えば、2024年7月に英国健康安全保障局が発表した2023年の新規STI診断件数は401,800件で、2022年の383,789件から4.7％増加しました。従って、性病の蔓延は膣炎治療薬市場の拡大に拍車をかける可能性が高いです。

生殖能力の動向の変化も、今後数年間の膣炎治療薬市場を押し上げる構えです。生殖能力とは、生物、人、集団が本来持っている子供を持つ能力を示すもので、人間の生物学において重要な側面です。膣炎治療薬は、生殖の健康に影響を与える可能性のある根本的な感染症や病気に対処することで、生殖能力を高める可能性があります。2023年6月現在、米国疾病予防管理センター（Centers for Disease Control and Prevention）による人口動態統計速報（Vital Statistics Rapid Release）では、2021年からの出生率が1％未満とわずかに低下し、15歳から44歳の女性1,000人当たりの出生数は56.1人となった。このように、出生動向の変化は膣炎治療薬市場の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界膣炎治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の膣炎治療薬市場：成長率分析
• 世界の膣炎治療薬市場の実績：規模と成長, 2019-2024
• 世界の膣炎治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界膣炎治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の膣炎治療薬市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ニトロイミダゾール化合物
• リンコサミド抗生物質
• トリアゾール
• イミダゾール
• 世界の膣炎治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 皮膚
• 膣
• 世界の膣炎治療薬市場適応症の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 細菌性膣炎
• トリコモナス症
• 外陰膣カンジダ症
• その他のタイプ
• 世界の膣炎治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 外来手術センター
• 専門婦人科センター
• クリニック
• 世界の膣炎治療薬市場ニトロイミダゾール化合物のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• メトロニダゾール
• チニダゾール
• 世界の膣炎治療薬市場リンコサミド系抗生物質の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• クリンダマイシン
• 世界の膣炎治療薬市場、トリアゾールのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• フルコナゾール
• イトラコナゾール
• 世界の膣炎治療薬市場、イミダゾールのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クロトリマゾール
• ミコナゾール

第7章 地域別・国別分析

• 世界の膣炎治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の膣炎治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 膣炎治療薬市場：競合情勢
• 膣炎治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Lupin Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Symbiomix Therapeutics Inc.
• Mission Pharmacal Company
• Teva Pharmaceutical Industries Ltd.
• Janssen Pharmaceuticals Inc.
• Lumavita AG
• Abbott Laboratories Ltd.
• GlaxoSmithKline plc
• Sanofi SA
• Bristol-Myers-Squibb Co
• Eli Lilly and Co
• TherapeuticsMD Inc.
• Scynexis Inc.
• Sebela Pharmaceuticals Inc.
• Dare Bioscience Inc.
• Hologic Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 膣炎治療薬市場2029：新たな機会を提供する国
• 膣炎治療薬市場2029：新たな機会を提供するセグメント
• 膣炎治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Vaginitis therapeutics involves the utilization of drugs, such as antifungal agents, antibiotics, and hormonal medications, for the treatment of vaginal infections. These drugs effectively alleviate symptoms such as itching, discharge, and pain.

The primary drug types for vaginitis therapeutics include nitroimidazole compounds, lincosamide antibiotics, triazoles, and imidazoles. Nitroimidazoles encompass a group of antimicrobial medications effective against parasites, mycobacteria, and anaerobic gram-positive and gram-negative bacteria. These drugs can be administered orally, topically, or vaginally, and they are indicated for conditions such as bacterial vaginosis, trichomoniasis, vulvovaginal candidiasis, and others. End users for these therapeutics include hospitals, ambulatory surgical centers, specialized gynecology centers, and clinics.

The vaginitis therapeutics market research report is one of a series of new reports from The Business Research Company that provides vaginitis therapeutics market statistics, including vaginitis therapeutics industry global market size, regional shares, competitors with a vaginitis therapeutics market share, detailed vaginitis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the vaginitis therapeutics industry. This vaginitis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vaginitis therapeutics market size has grown strongly in recent years. It will grow from$4.07 billion in 2024 to $4.47 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to high incidence of vaginal infections, women's health awareness, change in lifestyles and hygiene practices, antibiotic resistance concerns, pharmaceutical research and development

The vaginitis therapeutics market size is expected to see rapid growth in the next few years. It will grow to $6.72 billion in 2029 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to rising emphasis on personalized medicine, increased healthcare access, growing aging population, focus on non-antibiotic therapies, awareness and education initiatives. Major trends in the forecast period include combination therapies for resistant cases, regulatory advances and guidelines, integration of digital health tools, global collaboration for research, development of non-drug therapies.

The rising prevalence of sexually transmitted diseases (STDs) is expected to drive the growth of the vaginitis therapeutics market in the future. STDs are infections transmitted through sexual contact between infected and uninfected individuals, and they can cause vaginitis, which leads to vaginal inflammation and pain. Vaginitis therapeutics are designed to alleviate the symptoms associated with vaginitis caused by STDs, resulting in higher usage of these medications among women. For instance, in July 2024, the UK Health Security Agency reported that there were 401,800 new diagnoses of STIs in 2023, reflecting a 4.7% increase from 2022's 383,789 cases. Therefore, the growing prevalence of STDs is likely to fuel the expansion of the vaginitis therapeutics market.

Changing fertility trends are also poised to boost the vaginitis therapeutics market in the forthcoming years. Fertility, denoting the inherent capacity of an organism, person, or group to have children, is a critical aspect of human biology. Vaginitis therapeutics may enhance fertility by addressing underlying infections or illnesses that could impact reproductive health. Notably, as of June 2023, the Vital Statistics Rapid Release report from the Centers for Disease Control and Prevention highlighted a marginal decrease of less than 1% in the overall fertility rate from 2021, settling at 56.1 births per 1,000 women aged 15 to 44. Thus, changing fertility trends serve as a driving force behind the vaginitis therapeutics market.

Product innovation stands out as a prominent trend gaining traction in the vaginitis therapeutics market. Leading companies in this market are dedicated to developing inventive solutions to fortify their market presence. For example, Duchesnay Inc., a Canada-based pharmaceutical company specializing in women's health, introduced Vablys, the pioneering prescription antiseptic and anti-infective treatment tailored for bacterial vaginosis in women under 55 years of age. With multiple modes of action and anti-infective properties against various pathogens, the treatment involves the insertion of one tablet into the vagina at bedtime for six consecutive days.

Major companies in the vaginal health diagnostics market are focusing on developing advanced products, such as comprehensive diagnostic tools, to enhance the accuracy and speed of diagnosing vaginal infections, ultimately improving patient outcomes and streamlining treatment protocols. These comprehensive diagnostic tools are sophisticated testing systems designed to accurately identify multiple health conditions or pathogens simultaneously, thereby improving diagnostic efficiency and patient care. For example, in November 2022, Cepheid, a US-based molecular diagnostics company, launched the Multiplex Vaginal Panel. This diagnostic tool utilizes polymerase chain reaction (PCR) technology to simultaneously detect various pathogens associated with vaginitis, including bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis, from a single vaginal swab sample. This comprehensive testing method enables rapid identification of the causative agents of vaginal infections, facilitating timely and targeted treatment while reducing the risk of misdiagnosis and ineffective therapies. By providing results in approximately 60 minutes, the panel significantly narrows the test-to-treatment gap, enhancing patient outcomes in the management of vaginitis.

In March 2023, GSK, a UK-based pharmaceutical and biotechnology company, partnered with SCYNEXIS to develop and commercialize innovative treatments for fungal infections. This collaboration seeks to combine GSK's extensive global reach with SCYNEXIS's expertise in antifungal therapies to improve patient outcomes in the treatment of serious fungal diseases. SCYNEXIS is a US-based biotechnology company focused on developing medicines for fungal infections.

Major companies operating in the vaginitis therapeutics market include Pfizer Inc., Merck & Co Inc., Novartis AG, Bayer AG, Lupin Pharmaceuticals Inc., Symbiomix Therapeutics Inc., Mission Pharmacal Company, Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals Inc., Lumavita AG, Abbott Laboratories Ltd., GlaxoSmithKline plc, Sanofi SA, Bristol-Myers-Squibb Co, Eli Lilly and Co, TherapeuticsMD Inc., Scynexis Inc., Sebela Pharmaceuticals Inc., Dare Bioscience Inc., Hologic Inc., Mylan N.V., Viamet Pharmaceuticals Inc., Matinas BioPharma Holdings Inc., Cidara Therapeutics Inc., Imprimis Pharmaceuticals Inc., Innovus Pharmaceuticals Inc., Evofem Biosciences Inc., Mycovia Pharmaceuticals, Perrigo Company plc, Mithra Pharmaceuticals, Ferring Pharmaceuticals, AstraZeneca plc, Biocon Limited, Pacira Pharmaceuticals Inc., The Medicines Company

North America was the largest region in the global vaginitis therapeutics market in 2024. The regions covered in the vaginitis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the vaginitis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The vaginitis therapeutics market includes revenues earned by entities by nonhormonal therapy, and antioxidant therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vaginitis Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vaginitis therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vaginitis therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vaginitis therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Nitroimidazole Compound; Lincosamide Antibiotics; Triazoles; Imidazoles
• 2) By Route Of Administration: Oral; Cutaneous; Vaginal
• 3) By Indication Type: Bacterial Vaginosis; Trichomoniasis; Vulvovaginal Candidiasis; Other Types
• 3) By End Users: Hospitals; Ambulatory Surgical Centers; Specialized Gynecology Centers; Clinics
• Subsegments:
• 1) By Nitroimidazole Compound: Metronidazole; Tinidazole
• 2) By Lincosamide Antibiotics: Clindamycin
• 3) By Triazoles: Fluconazole; Itraconazole
• 4) By Imidazoles: Clotrimazole; Miconazole
• Companies Mentioned: Pfizer Inc.; Merck & Co Inc.; Novartis AG; Bayer AG; Lupin Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vaginitis Therapeutics Market Characteristics

3. Vaginitis Therapeutics Market Trends And Strategies

4. Vaginitis Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Vaginitis Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Vaginitis Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Vaginitis Therapeutics Market Growth Rate Analysis
• 5.4. Global Vaginitis Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Vaginitis Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Vaginitis Therapeutics Total Addressable Market (TAM)

6. Vaginitis Therapeutics Market Segmentation

• 6.1. Global Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nitroimidazole Compound
• Lincosamide Antibiotics
• Triazoles
• Imidazoles
• 6.2. Global Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Cutaneous
• Vaginal
• 6.3. Global Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bacterial Vaginosis
• Trichomoniasis
• Vulvovaginal Candidiasis
• Other Types
• 6.4. Global Vaginitis Therapeutics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Surgical Centers
• Specialized Gynecology Centers
• Clinics
• 6.5. Global Vaginitis Therapeutics Market, Sub-Segmentation Of Nitroimidazole Compound, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Metronidazole
• Tinidazole
• 6.6. Global Vaginitis Therapeutics Market, Sub-Segmentation Of Lincosamide Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clindamycin
• 6.7. Global Vaginitis Therapeutics Market, Sub-Segmentation Of Triazoles, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fluconazole
• Itraconazole
• 6.8. Global Vaginitis Therapeutics Market, Sub-Segmentation Of Imidazoles, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clotrimazole
• Miconazole

7. Vaginitis Therapeutics Market Regional And Country Analysis

• 7.1. Global Vaginitis Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Vaginitis Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vaginitis Therapeutics Market

• 8.1. Asia-Pacific Vaginitis Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vaginitis Therapeutics Market

• 9.1. China Vaginitis Therapeutics Market Overview
• 9.2. China Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vaginitis Therapeutics Market

• 10.1. India Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vaginitis Therapeutics Market

• 11.1. Japan Vaginitis Therapeutics Market Overview
• 11.2. Japan Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vaginitis Therapeutics Market

• 12.1. Australia Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vaginitis Therapeutics Market

• 13.1. Indonesia Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vaginitis Therapeutics Market

• 14.1. South Korea Vaginitis Therapeutics Market Overview
• 14.2. South Korea Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vaginitis Therapeutics Market

• 15.1. Western Europe Vaginitis Therapeutics Market Overview
• 15.2. Western Europe Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vaginitis Therapeutics Market

• 16.1. UK Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vaginitis Therapeutics Market

• 17.1. Germany Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vaginitis Therapeutics Market

• 18.1. France Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vaginitis Therapeutics Market

• 19.1. Italy Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vaginitis Therapeutics Market

• 20.1. Spain Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vaginitis Therapeutics Market

• 21.1. Eastern Europe Vaginitis Therapeutics Market Overview
• 21.2. Eastern Europe Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vaginitis Therapeutics Market

• 22.1. Russia Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vaginitis Therapeutics Market

• 23.1. North America Vaginitis Therapeutics Market Overview
• 23.2. North America Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vaginitis Therapeutics Market

• 24.1. USA Vaginitis Therapeutics Market Overview
• 24.2. USA Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vaginitis Therapeutics Market

• 25.1. Canada Vaginitis Therapeutics Market Overview
• 25.2. Canada Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vaginitis Therapeutics Market

• 26.1. South America Vaginitis Therapeutics Market Overview
• 26.2. South America Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vaginitis Therapeutics Market

• 27.1. Brazil Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vaginitis Therapeutics Market

• 28.1. Middle East Vaginitis Therapeutics Market Overview
• 28.2. Middle East Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vaginitis Therapeutics Market

• 29.1. Africa Vaginitis Therapeutics Market Overview
• 29.2. Africa Vaginitis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Vaginitis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Vaginitis Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vaginitis Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Vaginitis Therapeutics Market Competitive Landscape
• 30.2. Vaginitis Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Lupin Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Vaginitis Therapeutics Market Other Major And Innovative Companies

• 31.1. Symbiomix Therapeutics Inc.
• 31.2. Mission Pharmacal Company
• 31.3. Teva Pharmaceutical Industries Ltd.
• 31.4. Janssen Pharmaceuticals Inc.
• 31.5. Lumavita AG
• 31.6. Abbott Laboratories Ltd.
• 31.7. GlaxoSmithKline plc
• 31.8. Sanofi SA
• 31.9. Bristol-Myers-Squibb Co
• 31.10. Eli Lilly and Co
• 31.11. TherapeuticsMD Inc.
• 31.12. Scynexis Inc.
• 31.13. Sebela Pharmaceuticals Inc.
• 31.14. Dare Bioscience Inc.
• 31.15. Hologic Inc.

32. Global Vaginitis Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vaginitis Therapeutics Market

34. Recent Developments In The Vaginitis Therapeutics Market

35. Vaginitis Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Vaginitis Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Vaginitis Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Vaginitis Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer